S-HPABA, a marine fungal-derived bioactive compound, exhibits potent lipid-lowering efficacy and safety in modulating lipid dysregulation revealed by integrative lipidomics and molecular biology approaches.
- 1Department of Pharmaceutical Analysis, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China.
- 2Key Laboratory of Clinical Research on Respiratory and Digestive Diseases, Baoding Hospital of Beijing Children's Hospital Affiliated to Capital Medical University, Baoding, Hebei, China.
Abstract
Introduction
Hyperlipidemia is a widespread metabolic disorder that places a heavy burden on normal body functions. Given the drawbacks of current lipid-lowering drugs, there is considerable interest in developing alternative nutraceuticals from natural sources. S-2-(2-hydroxypropanamido) benzoic acid (S-HPABA) is a novel compound obtained for the first time from a marine fungus, which has demonstrated strong lipid-lowering effects in vitro and in vivo with an excellent safety profile.Methods
To investigate S-HPABA's mechanism of action, an integrated strategy of lipidomics and bioinformatics was adopted to screen candidate targets. The selected targets were then validated through RT-qPCR and western blotting.Results
The results indicated that 57 differential metabolites and 11 metabolic pathways were significantly regulated by S-HPABA. Based on the combined analyses, five targets were initially selected. Validation experiments showed that FASN, PLA2G2A and TYMP play crucial roles in the lipid-lowering process, with FASN being the most prominent.Discussion
Mechanistically, S-HPABA-induced reduction of lipid accumulation was associated with decreased FASN expression and PI3K/AKT/mTOR pathway inhibition. In summary, S-HPABA is a safe and potent lipid-lowering bioactive compound with promise as a functional food ingredient for metabolic health.
Related
- Immune-modulating copper-doped bioactive glass-based injectable hydrogel for periodontitis therapy
- Evaluation of the Anticancer Potential of Compound 107 via the VEGFA and VEGFR2 (KDR) Signaling Pathway in Colorectal Cancer: Integrative Analysis of Clinical, In Silico, and In Vitro Approaches
- Closing the Translational Gap in Tuberculosis Lipidomics for Resource-Constrained Settings
- Quantitative lipidomics reveals Lipid perturbation of plasma apoptotic extracellular vesicles during physiological aging
- Early diagnosis and molecular classification of gastric cancer peritoneal metastasis by deep learning-driven single-cell lipidomics
BibTeX
@article{jia2026shpaba,
title = {{S-HPABA, a marine fungal-derived bioactive compound, exhibits potent lipid-lowering efficacy and safety in modulating lipid dysregulation revealed by integrative lipidomics and molecular biology approaches.}},
author = {Xinming Jia and Menglu Yu and Dongang Shen and Hongyang Fu and Yuqing Wang and Xiao Wang and Jiaoyan Huang and Shilin Sun and Zhiguo Yu and Yuping Chen and Yunli Zhao},
journal = {Frontiers in nutrition},
year = {2026},
month = oct,
doi = {10.3389/fnut.2026.1855150},
url = {https://europepmc.org/article/MED/42898125},
note = {CC BY},
}
RIS
TY - JOUR
TI - S-HPABA, a marine fungal-derived bioactive compound, exhibits potent lipid-lowering efficacy and safety in modulating lipid dysregulation revealed by integrative lipidomics and molecular biology approaches.
AU - Xinming Jia
AU - Menglu Yu
AU - Dongang Shen
AU - Hongyang Fu
AU - Yuqing Wang
AU - Xiao Wang
AU - Jiaoyan Huang
AU - Shilin Sun
AU - Zhiguo Yu
AU - Yuping Chen
AU - Yunli Zhao
PY - 2026
DA - 2026/10/05
JO - Frontiers in nutrition
DO - 10.3389/fnut.2026.1855150
UR - https://europepmc.org/article/MED/42898125
AB - Introduction Hyperlipidemia is a widespread metabolic disorder that places a heavy burden on normal body functions. Given the drawbacks of current lipid-lowering drugs, there is considerable interest in developing alternative nutraceuticals from natural sources. S-2-(2-hydroxypropanamido) benzoic acid (S-HPABA) is a novel compound obtained for the first time from a marine fungus, which has demonstrated strong lipid-lowering effects in vitro and in vivo with an excellent safety profile.Methods To investigate S-HPABA's mechanism of action, an integrated strategy of lipidomics and bioinformatics was adopted to screen candidate targets. The selected targets were then validated through RT-qPCR and western blotting.Results The results indicated that 57 differential metabolites and 11 metabolic pathways were significantly regulated by S-HPABA. Based on the combined analyses, five targets were initially selected. Validation experiments showed that FASN, PLA2G2A and TYMP play crucial roles in the lipid-lowering process, with FASN being the most prominent.Discussion Mechanistically, S-HPABA-induced reduction of lipid accumulation was associated with decreased FASN expression and PI3K/AKT/mTOR pathway inhibition. In summary, S-HPABA is a safe and potent lipid-lowering bioactive compound with promise as a functional food ingredient for metabolic health.
SN - 2296-861X
ER -